Mounjaro History & Development: How Tirzepatide Went From Lab to Clinic

What Is Tirzepatide and Where Did the Idea Come From?

Tirzepatide is a synthetic 39-amino-acid peptide that acts as a dual agonist at two incretin hormone receptors: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). The molecule is not a simple combination of two existing drugs. Eli Lilly's chemists engineered a single peptide backbone that binds both receptor types with high affinity, then attached a C20 fatty diacid moiety to extend its half-life to approximately five days, enabling once-weekly dosing [1].

The conceptual roots go back decades. Researchers had known since the 1970s that GIP and GLP-1 together account for the majority of the postprandial insulin response, a phenomenon called the "incretin effect." By the early 2000s, GLP-1 receptor agonists (exenatide, 2005; liraglutide, 2010) were already reaching patients. GIP, however, was largely dismissed as a therapeutic target after early data suggested that GIP's insulinotropic action was blunted in people with type 2 diabetes [2].

Why GIP Was Reconsidered

The pivot came from animal studies showing that GIP receptor activation, when combined with GLP-1 receptor activation, produced synergistic effects on fat tissue, appetite signaling, and pancreatic beta-cell function that neither agonist produced alone [3]. A 2013 paper in Diabetes by Finan and colleagues at Lilly showed that a dual GIP/GLP-1 peptide outperformed either selective agonist in diet-induced obese mice, validating the dual-receptor concept before human trials began [4].

The "Twincretin" Label

The scientific community began calling tirzepatide a "twincretin" to distinguish it from single-receptor GLP-1 agonists like semaglutide and liraglutide. The term captured the dual-hormone strategy but also invited scrutiny: would the GIP component add clinical benefit or just noise? The SURPASS trial program was designed, in part, to answer that question head-on.

Preclinical Development and Molecular Design

Eli Lilly's medicinal chemistry team spent several years optimizing the peptide sequence before settling on the tirzepatide structure. The molecule is based on the native GIP sequence but incorporates amino acid substitutions that improve GLP-1 receptor binding and resist enzymatic degradation by dipeptidyl peptidase-4 (DPP-4) [1].

Fatty Acid Conjugation and Half-Life Engineering

The C20 fatty diacid chain attached at lysine-26 binds non-covalently to albumin in the bloodstream. This albumin binding slows renal clearance and protects the peptide from proteolysis, extending the effective half-life to roughly 116 hours in humans. That pharmacokinetic profile translates directly to once-weekly subcutaneous dosing with a stable steady-state concentration by week four [1].

Receptor Selectivity Ratios

Tirzepatide shows approximately equal potency at GIP and GLP-1 receptors in cell-based assays, with EC50 values in the low nanomolar range for both. This is a deliberate design choice. Earlier dual agonists in development had skewed ratios that effectively made them GLP-1-dominant with marginal GIP activity. Lilly's team concluded from rodent dose-response data that balanced dual agonism produced the greatest metabolic signal [4].

Phase 1 human pharmacology studies confirmed dose-proportional exposure, a half-life supporting weekly dosing, and no unexpected immunogenicity signals, clearing the path to Phase 2 [5].

Phase 2 Dose-Finding: Establishing the Clinical Range

A dose-ranging Phase 2 trial published in The Lancet in 2018 enrolled 316 adults with type 2 diabetes inadequately controlled on metformin [6]. Participants received tirzepatide 1 mg, 5 mg, 10 mg, or 15 mg once weekly, or placebo, for 26 weeks.

Key Phase 2 Findings

The 15 mg dose produced a mean A1C reduction of 2.4 percentage points from a baseline of approximately 8.0%, with a corresponding body weight reduction of 11.3 kg. Nausea and vomiting were the most common adverse events, predominantly mild to moderate and concentrated in the first eight weeks of treatment. The dose-response relationship was clear enough that Lilly selected 5 mg, 10 mg, and 15 mg as the Phase 3 doses, with a 2.5 mg starting dose to improve early tolerability [6].

The Phase 2 data also revealed something unexpected: the weight loss signal at 15 mg exceeded what had been observed with any approved GLP-1 receptor agonist at the time, including semaglutide 1 mg. That finding set the stage for the headline-generating SURPASS program.

The SURPASS Phase 3 Program: Five Trials, One Drug

Eli Lilly designed the SURPASS (Tirzepatide Once Weekly as Add-on Therapy to Metformin for the Treatment of Type 2 Diabetes) program as five concurrent Phase 3 trials, each targeting a different clinical context. This was one of the most extensive pre-approval diabetes trial programs ever run for a single molecule.

SURPASS-1: Monotherapy

SURPASS-1 enrolled 478 adults with type 2 diabetes not on background glucose-lowering therapy. At 40 weeks, tirzepatide 15 mg reduced A1C by 2.07 percentage points versus 0.03 percentage points for placebo. Body weight fell by 9.5 kg in the 15 mg group [7]. The trial established that tirzepatide works as a standalone agent, not just as an add-on.

SURPASS-2: Head-to-Head vs. Semaglutide 1 mg

SURPASS-2 is the most-cited trial in the program. Published in the New England Journal of Medicine in 2021 (N=1,879), it compared tirzepatide 5 mg, 10 mg, and 15 mg against open-label semaglutide 1 mg over 40 weeks in adults with type 2 diabetes on metformin [8].

Tirzepatide 15 mg reduced A1C by 2.46 percentage points compared with 1.86 percentage points for semaglutide 1 mg (difference: 0.60 percentage points; P<0.001). Body weight fell by 12.4 kg with tirzepatide 15 mg versus 6.2 kg with semaglutide 1 mg. The proportion of patients reaching the A1C target of <7.0% was 92% in the tirzepatide 15 mg group versus 81% in the semaglutide group [8].

Dr. Juan Pablo Frías, the lead investigator, wrote: "These results suggest that dual targeting of GIP and GLP-1 receptors with tirzepatide provides greater glycaemic and body weight reductions than selective GLP-1 receptor agonism with semaglutide" [8].

SURPASS-3: vs. Insulin Degludec

SURPASS-3 (N=1,444) compared tirzepatide against titrated insulin degludec over 52 weeks in adults on metformin with or without an SGLT2 inhibitor [9]. Tirzepatide 15 mg produced A1C reductions of 2.37 percentage points versus 1.34 percentage points for insulin degludec, with a weight reduction of 12.9 kg versus a weight gain of 2.3 kg in the insulin arm. The finding has direct clinical relevance for patients who would otherwise initiate basal insulin [9].

SURPASS-4 and SURPASS-5

SURPASS-4 (N=2,002) studied patients at high cardiovascular risk on sulfonylureas and metformin, comparing tirzepatide against insulin glargine U-100 over 104 weeks. Tirzepatide maintained superior A1C reductions throughout and produced consistent weight loss [10]. SURPASS-5 (N=475) evaluated tirzepatide added to insulin glargine, demonstrating that the drug works safely in combination with basal insulin without an unacceptable increase in hypoglycemia [11].

FDA Approval: May 2022

The FDA approved tirzepatide under the brand name Mounjaro on May 13, 2022, for the treatment of type 2 diabetes as an adjunct to diet and exercise [12]. The approval covered doses of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg, all delivered via the KwikPen single-dose autoinjector.

The prescribing label carries a boxed warning for thyroid C-cell tumors, consistent with the GLP-1 receptor agonist class, based on rodent carcinogenicity data. The warning does not apply to humans with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, for whom the drug is contraindicated [12].

What Made the Approval Straightforward

The FDA's review was aided by the breadth of the SURPASS program. With more than 6,000 patients across five trials, the agency had an unusually complete picture of the drug's efficacy and safety profile before approval. The cardiovascular outcomes data from SURPASS-4 (104 weeks) also gave regulators confidence about intermediate-term safety, though a dedicated cardiovascular outcomes trial (SURPASS-CVOT) was required as a post-marketing commitment [10].

Mechanism of Action: How Tirzepatide Works

Tirzepatide binds and activates both the GIP receptor (GIPR) and the GLP-1 receptor (GLP-1R), which are expressed in the pancreas, brain, adipose tissue, and gastrointestinal tract.

Pancreatic Effects

At the pancreatic beta cell, GIP and GLP-1 receptor activation both stimulate cyclic AMP production, which amplifies glucose-stimulated insulin secretion. The key qualifier is "glucose-stimulated." Both receptors are silent when blood glucose is in the normal fasting range, which explains why tirzepatide carries a low intrinsic risk of hypoglycemia as monotherapy [1]. At the alpha cell, GLP-1 receptor activation suppresses glucagon secretion, reducing hepatic glucose output after meals.

Central and Adipose Effects

GIP receptors in the hypothalamus may reduce food intake and appetite, and GIP receptors in adipocytes influence fatty acid storage and lipolysis. The combination of central appetite suppression (driven largely by GLP-1 receptor signaling) with GIP-mediated adipose effects may explain why tirzepatide produces greater weight loss than GLP-1 receptor agonists alone [3].

Gastric Emptying

Both GIP and GLP-1 receptors slow gastric emptying, increasing postprandial satiety. This effect is most pronounced early in treatment and partially attenuates over time, which is thought to contribute to the nausea that peaks in the first four to eight weeks and then subsides for most patients [6].

SURMOUNT Program: Tirzepatide for Obesity

While SURPASS addressed type 2 diabetes, Eli Lilly simultaneously ran the SURMOUNT program in adults with obesity or overweight without diabetes.

SURMOUNT-1 Results

SURMOUNT-1 (N=2,539) enrolled adults with a BMI of 30 or above, or a BMI of 27 or above with at least one weight-related complication, who did not have type 2 diabetes [13]. At 72 weeks, tirzepatide 15 mg produced a mean weight reduction of 22.5% from baseline versus 2.4% for placebo. 37.0% of participants in the 15 mg group lost 25% or more of their body weight, a threshold not previously reached in any large randomized controlled trial of a pharmacological agent [13].

These numbers prompted the FDA to approve tirzepatide for chronic weight management under the brand name Zepbound in November 2023 [14].

The table below summarizes the weight loss outcomes across the SURPASS and SURMOUNT programs, giving clinicians a side-by-side view that the individual trial publications do not present together.

| Trial | Population | Duration | Tirzepatide Dose | Weight Change (Active) | Weight Change (Comparator) | |---|---|---|---|---|---| | SURPASS-1 | T2D, no background therapy | 40 wk | 15 mg | -9.5 kg | -0.9 kg (placebo) | | SURPASS-2 | T2D on metformin | 40 wk | 15 mg | -12.4 kg | -6.2 kg (sema 1 mg) | | SURPASS-3 | T2D on metformin ± SGLT2i | 52 wk | 15 mg | -12.9 kg | +2.3 kg (degludec) | | SURMOUNT-1 | Obesity, no T2D | 72 wk | 15 mg | -22.5% | -2.4% (placebo) |

Tirzepatide vs. Semaglutide: Where the Data Stand

The SURPASS-2 head-to-head comparison used semaglutide 1 mg, which is the approved diabetes dose but not the 2.4 mg dose used for weight management (Wegovy). No randomized head-to-head trial directly comparing tirzepatide 15 mg to semaglutide 2.4 mg in the same population has been published as of mid-2025. Indirect comparisons from network meta-analyses consistently favor tirzepatide on both A1C and weight endpoints, but those analyses carry methodological limitations that prevent definitive conclusions [15].

The 2023 American Diabetes Association Standards of Care recommend GLP-1 receptor agonists and dual GIP/GLP-1 agonists as preferred second-line agents for patients with type 2 diabetes who need weight loss or have established cardiovascular disease, positioning tirzepatide explicitly within the therapeutic algorithm [16].

Cardiovascular and Renal Signals

The SURPASS-CVOT trial (SURPASS-4 extension and a dedicated outcomes trial) is ongoing. Interim data from SURPASS-4 across 104 weeks showed that the rate of major adverse cardiovascular events (MACE) with tirzepatide was numerically lower than with insulin glargine, though the trial was not powered to confirm cardiovascular superiority [10].

A 2024 analysis in the New England Journal of Medicine examining SURMOUNT-MMO, a cardiovascular outcomes trial in obese patients without diabetes, is expected to report results in 2025 and will provide the most definitive cardiovascular data to date.

Separate Phase 3 trials (SURPASS-KIDNEY) are evaluating tirzepatide's effects on estimated GFR and albuminuria in chronic kidney disease, an area where GLP-1 receptor agonists have already demonstrated benefit [17].

Manufacturing, Supply, and the Shortage Problem

Tirzepatide is manufactured at Eli Lilly's facilities in Indiana and Ireland. Following FDA approval in May 2022, demand substantially outpaced supply. The FDA placed tirzepatide on its drug shortage list in late 2022, a designation that persisted through much of 2023 [18]. The shortage drove a parallel market of compounded tirzepatide, which the FDA flagged as potentially unsafe because compounders lack access to the proprietary manufacturing processes and cannot guarantee bioequivalence [18].

Lilly expanded production capacity through 2023 and 2024, and the FDA removed tirzepatide from its shortage list in late 2024 after supply stabilized.